Skip to main
NPCE
NPCE logo

NeuroPace (NPCE) Stock Forecast & Price Target

NeuroPace (NPCE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroPace Inc. has demonstrated a significant improvement in patients' quality of life through its RNS system for epilepsy, with a measurable increase of 3.2 points on the QOLIE-89 survey after one year of treatment. The company has also benefitted from favorable macro trends, evidenced by a growth in comprehensive epilepsy centers (CECs) from 151 in 2012 to 256 in 2019, alongside a 150% increase in epileptologists per capita, enhancing access to care. Additionally, NeuroPace recorded a notable revenue growth of 75.5% between 2022 and 2024, showcasing a positive inflection in its financial performance.

Bears say

NeuroPace Inc faces a challenging financial outlook characterized by a persistent history of significant net losses, with expectations to continue incurring losses in the near term, raising concerns about achieving or sustaining profitability. The company may require additional capital to fund its operations, which poses risks of unfavorable terms and potential cost-cutting measures that could further jeopardize its business. Existing financial obligations, including a restrictive term loan and uncertainties surrounding an expiring distribution agreement, add further complexity to the company's financial stability and stock performance.

NeuroPace (NPCE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroPace (NPCE) Forecast

Analysts have given NeuroPace (NPCE) a Buy based on their latest research and market trends.

According to 5 analysts, NeuroPace (NPCE) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroPace (NPCE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.